Daridorexant (Quviviq)
Canadian Journal of Health Technologies · 02.03.2026 · 6 (3)
DOI: 10.51731/cjht.2026.1363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 02.03.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Daridorexant (Quviviq), 25 mg oral tablet, 50 mg oral tablet. Indication: Quviviq (daridorexant) is indicated for the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Zitieren
APA
CDA-AMC (2026). Daridorexant (Quviviq). Canadian Journal of Health Technologies, 6(3). https://doi.org/10.51731/cjht.2026.1363
Vancouver
CDA-AMC. Daridorexant (Quviviq). Canadian Journal of Health Technologies. 2026;6(3). doi:10.51731/cjht.2026.1363
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Daridorexant (Quviviq)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {3},
doi = {10.51731/cjht.2026.1363}
}
EUVIMED